- Junshi Bio out-licensed US-Canada rights for its anti-PD-1 antibody to Coherus Bio in an agreement worth up to $1.1 billion.
- Adagene will license its SAFEbody™ technology platform to Exelixis (EXEL) for use in Exelixis' ADC preclinical pipeline.
- Innovent Biologics and its partner Eli Lilly announced China approved its supplemental NDA of their partnered anti-PD-1 drug, Tyvyt® (sintilimab injection), as a first-line treatment for nonsquamous non-small cell lung cancer.
For further details see:
Week In Review: Junshi Signs $1.1 Billion Deal For U.S.-Canada Rights To PD-1